Results: 4

1.
Figure 1

Figure 1. Cell growth.. From: Fatty Acid Metabolites in Rapidly Proliferating Breast Cancer.

MCF-7 (upper panels) and MDA-MB-231 (lower panels) cell cultures were challenged with a metabolite for 48 hr and assayed for cell density. One-way ANOVA gave the statistical significances shown between comparisons of cells treated with 0 (culture media) or 100 pM–1 µM of the indicated metabolite. Data are means ±SEM in ODU490 of 3–6 cultures.

Joseph T. O’Flaherty, et al. PLoS One. 2013;8(5):e63076.
2.
Figure 2

Figure 2. Metabolites and Mib1.. From: Fatty Acid Metabolites in Rapidly Proliferating Breast Cancer.

Levels of the metabolites are compared by tissue type (panel A), Mib1 score in malignant (panel B) or normal (panel C) tissue; and grade in malignant tissue (panel D). Probability values were defined by paired (panel A) or unpaired (panels B, C, and D) Student t-tests and were corrected for the 7 comparisons made in each panel by the false discovery rate method.

Joseph T. O’Flaherty, et al. PLoS One. 2013;8(5):e63076.
3.
Figure 4

Figure 4. FA and Mib1.. From: Fatty Acid Metabolites in Rapidly Proliferating Breast Cancer.

Levels of the indicated FA are presented as mass (upper panels) or percentage of total recovered FA (lower panels) in malignant (left panels) and normal (right panels) breast tissue of patients with high or low Mib1 scores. Comparison of the 7 FA parameters on the basis of high or low Mib1 score by Students t-test gave no significant differences even before correction for multiple comparisons; the same analysis in RBC and plasma likewise revealed no significant differences as a function of Mib1 scores (results not shown).

Joseph T. O’Flaherty, et al. PLoS One. 2013;8(5):e63076.
4.
Figure 3

Figure 3. Metabolites and other markers.. From: Fatty Acid Metabolites in Rapidly Proliferating Breast Cancer.

Malignant tissue levels of the indicated metabolites were compared for poorer or better prognoses by mitosis, nuclear pleomorphism, and tubule formation indices (panel A) or nodal metastasis (panel B). 13-HODE (panel C) and PGE2 (panel D) levels were compared by poorer vs. better prognoses for: race, African (closed bars) or Caucasian American (open bars); Her2 score, 2 & 3 (closed bars) or 0 & 1 (open bars); age >50 years (closed bars) or ≤50 years (open bars); body mass index (BMI) >30 (closed bars) or ≤30 (open bars); estrogen receptors (ER) negative (closed bars) or positive (open bars); triple negative (tri (−)) for estrogen, progesterone, & Her2 receptors (closed bars) or not (open bars); tumor size, >2 (closed bars) or ≤ 2 cm (open bars). p Values are from Students t-test corrected for the 3 comparisons in each component of growth (panel A), for the 7 metabolite comparisons (panel B), or for the 7 marker comparisons (panels C and D) by the false discovery rate method. Analysis of these two metabolites for progesterone receptors or for 15-HETE, 12-HETE, 5-HETE, 5-oxo-ETE, and PGD2 in all 8 marker categories found no significant differences (data not shown).

Joseph T. O’Flaherty, et al. PLoS One. 2013;8(5):e63076.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk